Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363040 | 1.00 | PARP1 (1.00) | PARP1POLBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2763527 | 0.95 | PARP1 (0.90) | PARP1POLBALDH1A1 | |
| SCHEMBL2763303 | 0.85 | PARP1 (0.75) | PARP1 | |
| SCHEMBL4071313 | 0.81 | PARP1 (0.75) | PARP1KMT2A | |
| SCHEMBL2764349 | 0.81 | PARP1 (1.00) | PARP1POLBALDH1A1 | |
| SCHEMBL14170079 | 0.81 | PARP1 (0.69) | PARP1ALDH1A1CYP2D6KDM4E | |
| SCHEMBL14170205 | 0.80 | PARP1 (0.69) | PARP1KMT2A | |
| SCHEMBL2763788 | 0.79 | PARP1 (0.65) | PARP1ALDH1A1 | |
| SCHEMBL14924227 | 0.79 | PARP1 (0.65) | PARP1 | |
| SCHEMBL2764315 | 0.79 | PARP1 (0.65) | PARP1ALDH1A1KMT2AKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | disclosed |
| WO-2019159168-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD. (IL) | 2019-08-22 | — | — | WO | disclosed |
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-7268143-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | JAGTAP PRAKASH (US) | 2005-03-03 | — | — | US | disclosed |
| US-6828319-B2 | Antiinflamamtory agents; strokes; cardiovascular disorders | INOTEK PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| EP-1420785-A2 | SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-09-11 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885POLB 661/4885ALDH1A1 1165/4885 |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | PARP1 3794/4885POLB 3042/4885ALDH1A1 2105/4885 |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | CYP1B1, UGT1A1, CYP4B1 | PARP1 337/4885POLB 1794/4885ALDH1A1 553/4885 |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | PARP1 1207/4885POLB 4258/4885ALDH1A1 1473/4885 |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885POLB 661/4885ALDH1A1 1165/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885POLB 661/4885ALDH1A1 1165/4885 |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | PARP1 363/4885POLB 661/4885ALDH1A1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.